ЧТО ИЗВЕСТНО О НАТРИЙ-ГЛЮКОЗНОМ КО-ТРАНСПОРТЕРЕ 1 ТИПА?
Ключевые слова:
: ингибиторы натрий-глюкозного транспортера 1 типа, ингибиторы натрий глюкозного ко-транспортера 2 типа, сахарный диабет 2 типа, канаглифлозин, сотаглифлозин, мизаглифлозинАннотация
Из многочисленных исследований известно о роли ингибиторов НГЛТ-2 в снижении уровня глюкозы крови, кардио- и нефропротекции у пациентов с СД 2 типа. Несколько меньше изучен НГЛТ-1 типа, управление и активность которого также может быть ключом к компенсации СД 2 типа, хронических заболеваний сердца, почек и других, органов и тканей. На данный момент ингибирование НГЛТ-1 у людей может быть достигнуто только применением комбинированных ингибиторов НГЛТ-1/НГЛТ-2. Препараты с селективным ингибированием НГЛТ-1 активно изучаются на экспериментальных животных и в исследованиях in vitro. Настоящий обзор посвящен механизмам действия натрий-глюкозного ко-транспортера 1 типа, влияния ингибирования НГЛТ-1 на патологические процессы, а также оценены перспективы применения иНГЛТ-1 у людей.
Библиографические ссылки
Archana M. Navale1 & Archana N. Paranjape Glucose transporters: physiological and pathological roles. Biophys Rev (2016) 8:5–9. https://link.springer.com/article/10.1007/s12551-015-0186-2.
Bhatt D.L., Szarek M., Steg P.G., et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128. https://doi.org/10.1056/nejmoa2030183.
Bruckert C, Matsushita K, Mroueh A, et al. Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: role of endothelial SGLT1 and 2. Vascul Pharmacol. 2022;146:107095. https://doi.org/10.1016/j.vph.2022.107095
Dominguez Rieg J.D., Chirasani V., Koepsell H., et al. Regulation of intestinal SGLT1 by catestatin in hyperleptinemic type 2 diabetic mice. FASEB J. 2015;29:A970.9. https://doi.org/10.1038/labinvest.2015.129.
Ducroc R, Guilmeau S, Akashi K, et al. Luminal leptin induces rapid inhibition of active intestinal absorption of glucose mediated by sodium-glucose co-transporter 1. Diabetes. 2005; 54: 348–354. https://doi.org/10.2337/diabetes.54.2.348.
Dyer J, Hosie K.B., Shirazi-Beechey S.P. Nutrient regulation of human intestinal sugar transporter (SGLT1) expression. Gut 1997; 41: 56–59. http://dx.doi.org/10.1136/gut.41.1.56.
Ferraris R.P., Diamond J. Regulation of intestinal sugar transport. Physiol Rev 1997; 77: 257–302. https://doi.org/10.1152/physrev.1997.77.1.257.
Gallo L.A., Wright E.M., Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diabetes Vasc Dis Re. 2015; 12:78–89. https://doi.org/10.1177/1479164114561992.
Gorboulev V., Schurmann A., Vallon V., et al. Na+-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose-absorption and glucose-dependent incretin secretion. Diabetes. 2012; 61:187–196. https://doi.org/10.2337/db11-1029.
Hediger M.A., Coady M.J., Ikeda T.S., et al. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature 1987; 330: 379–381. https://www.nature.com/articles/330379a0.
Hirsch J.R., Loo D.D., Wright E.M. Regulation of Na+/glucose cotransporter expression by protein kinases in Xenopus laevis oocytes. J Biol Chem 1996; 271: 14740–14746. https://doi.org/10.1074/jbc.271.25.14740
Ishida N, Saito M, Sato S, Koepsell H, Taira E, Hirose M. SGLT1 participates in the development of vascular cognitive impair-ment in a mouse model of small vessel disease. Neurosci Lett. 2020;727:134929 https://doi.org/10.1016/j.neulet.2020.134929
Ishida, N., Saito, M., Sato, S., Tezuka, Y., Sanbe, A., Taira, E., … & Hirose, M. (2021). Mizagliflozin, a selective sglt1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease. Pharmacology Research &Amp; Perspectives, 9(5). https://doi.org/10.1002/prp2.869
Ishikawa Y., Eguchi T., Ishida H. Mechanism of betaadrenergic agonist-induced transmural transport of glucose in rat small intestine. Regulation of phosphorylation of SGLT1 controls the function. Biochim Biophys Acta 1997; 1357: 306–318. https://doi.org/10.1016/S0167-4889(97)00043-8.
Kaji K., Nishimura N., Seki K., Sato S., Saikawa S., Nakanishi K., Furukawa M., Kawaratani H., Kitade M., Moriya K., Namisaki T., Yoshiji H. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer. 2018 Apr 15;142(8):1712-1722. doi: 10.1002/ijc.31193 https://doi.org/10.1002/ijc.31193
Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Investig 1994; 93: 397–404. https://www.jci.org/articles/view/116972.
Mate A., Barfull A., Hermosa A.M., et al. Regulation of sodium-glucose cotransporter SGLT1 in the intestine of hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2006;291:760–767. http://dx.doi.org/10.1152/ajpregu.00524.2005
Numata S, McDermott JP, Sanchez G, Mitra A, Blanco G. The sodium-glucose cotransporter isoform 1 (SGLT-1) is important for sperm energetics, motility, and fertility†. Biol Reprod. 2022 Jun 13;106(6):1206-1217. https://doi.org/10.1093/biolre/ioac052.
Ramratnam M, Sharma R.K, D’Auria S, et al. Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. J Am Heart Assoc 2014; 3: e000899. https://doi.org/10.1161/JAHA.114.000899
Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018 Oct;61 (10):2079-2086. https://doi.org/10.1007/s00125-018-4654-7
Rieg T., Masuda T., Gerasimova M., et al. Increase in SGLT1-mediated trans-port explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014; 306:188–193. https://doi.org/10.1152/ajprenal.00518.2013.
Sano R, Shinozaki Y, Ohta T. Sodium-glucose cotransporters: Functional properties and pharmaceutical potential. J Diabetes Investig. 2020 Jul; 11(4):770-782. https://doi.org/10.1111/jdi.13255.
Sha S., Polidori D., Farrell K. et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab. 2015; 17(2): 188–97. https://doi.org/10.1111/dom.12418
Song P, Onishi A, Koepsell H, Vallon V (2016) Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets 20: 1109–1125. https://doi.org/10.1517/14728222.2016.1168808
Suga T, Kikuchi O, Kobayashi M, Matsui S, Yokota-Hashimoto H, Wada E, Kohno D, Sasaki T, Takeuchi K, Kakizaki S, Yamada M, Kitamura T. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol Metab. 2019 Jan;19:1-12. doi: 10.1016/j.molmet.2018.10.009 https://doi.org/10.1016/j.molmet.2018.10.009
Tavakkolizadeh A., Berger U.V., Shen K.R., et al. Diurnal rhythmicity in intestinal SGLT-1 function, V(max), and mRNA expression topography. Am J Physiol Gastrointest Liver Physiol 2001; 280: 209–215. https://doi.org/10.1152/ajpgi.2001.280.2.G209.
Wood I.S., Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003; 89: 3–9. https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/glucose-transporters-glut-and-sglt-expanded-families-of-sugar-transport-proteins/B4E2CD55D9FD41632B98F69E7BF754B0.
Zhao M, Li N, Zhou H. SGLT1: A Potential Drug Target for Cardiovascular Disease. Drug Des Devel Ther. 2023 Jul 6;17:2011-2023. https://doi.org/10.2147/DDDT.S418321.
Шестакова М.В., Аметов А.С., Анциферов М.Б., Бардымова Т.П., Валеева Ф.В., Галстян Г.Р., Демидова Т.Ю., Карпова И.А., Киселева Т.П., Майоров А.Ю., Мкртумян А.М., Недогода С.В., Петунина Н.А., Руяткина Л.А., Суплотова Л.А., Сухарева О.Ю., Фадеев В.В., Шамхалова М.Ш. Канаглифлозин: от гликемического контроля до улучшения сердечно-сосудистого и почечного прогноза у пациентов с сахарным диабетом 2 типа. Резолюция совета экспертов. Сахарный диабет. 2021;24(5):479-486. https://doi.org/10.14341/DM12848
